DGHS seeks NTAC’s opinion on mixed-dose vaccine
Dr Robed said that according to a Spanish publication, people who have taken Oxford-AstraZeneca vaccine as their first dose and mRNA or Pfizer as their second dose have shown a 30-40 times increase in Covid-19 antibodies, which is helpful in preventing coronavirus
The health directorate has asked the National Technical Advisory Committee (NTAC) on vaccination for its opinion on whether a mixed dose of vaccines from two separate vendors can be used to prevent coronavirus infections among people.
This information was given in the health bulletin on Wednesday by the spokesperson of the organization, Dr Robed Amin.
Dr Robed said that according to a Spanish publication, people who have taken Oxford-AstraZeneca vaccine as their first dose and mRNA or Pfizer as their second dose have shown a 30-40 times increase in Covid-19 antibodies, which is helpful in preventing coronavirus.
Keep updated, follow The Business Standard's Google news channel
Evidence of high antibody production has also been found in the bodies of those who received mRNA vaccines as the first dose and Oxford-AstraZeneca vaccine as the second dose, added Dr Robed.
Dr Robed said, "The time has come for us to consider whether this mixed-dose vaccine can be introduced in cases where the same vaccine is not available in large quantities. The NTAC on vaccination has been asked for its opinion in this regard."
